Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.

J Hepatol

Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Clayton, VIC 3008, Australia; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC 3004, Australia.

Published: May 2018

Background & Aims: In Iceland a nationwide program has been launched offering direct-acting antiviral (DAA) treatment for everyone living with hepatitis C virus (HCV). We estimate (i) the time and treatment scale-up required to achieve the World Health Organization's HCV elimination target of an 80% reduction in incidence; and (ii) the ongoing frequency of HCV testing and harm reduction coverage among people who inject drugs (PWID) required to minimize the likelihood of future HCV outbreaks occurring.

Methods: We used a dynamic compartmental model of HCV transmission, liver disease progression and the HCV cascade of care, calibrated to reproduce the epidemic of HCV in Iceland. The model was stratified according to injecting drug use status, age and stage of engagement. Four scenarios were considered for the projections.

Results: The model estimated that an 80% reduction in domestic HCV incidence was achievable by 2030, 2025 or 2020 if a minimum of 55/1,000, 75/1,000 and 188/1,000 PWID were treated per year, respectively (a total of 22, 30 and 75 of the estimated 400 PWID in Iceland per year, respectively). Regardless of time frame, this required an increased number of PWID to be diagnosed to generate enough treatment demand, or a 20% scale-up of harm reduction services to complement treatment-as-prevention incidence reductions. When DAA scale-up was combined with annual antibody testing of PWID, the incidence reduction target was reached by 2024. Treatment scale-up with no other changes to current testing and harm reduction services reduced the basic reproduction number of HCV from 1.08 to 0.59, indicating that future outbreaks would be unlikely.

Conclusion: HCV elimination in Iceland is achievable by 2020 with some additional screening of PWID. Maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that outbreaks are unlikely to occur once elimination targets have been reached.

Lay Summary: In Iceland, a nationwide program has been launched offering treatment for the entire population living with hepatitis C virus (HCV). A mathematical model was used to estimate the additional health system requirements to achieve the HCV elimination targets of the World Health Organization (WHO), as well as the year that this could occur. With some additional screening of people who inject drugs, Iceland could reach the WHO targets by 2020, becoming one of the first countries to achieve HCV elimination. The model estimated that once elimination targets were reached, maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that future HCV outbreaks are unlikely to occur.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2017.12.013DOI Listing

Publication Analysis

Top Keywords

harm reduction
20
hcv
16
hcv elimination
16
reduction services
16
elimination targets
12
iceland nationwide
8
nationwide program
8
program launched
8
launched offering
8
living hepatitis
8

Similar Publications

Introduction: Adults who switch from smoking cigarettes to use of electronic nicotine delivery systems (ENDS) may reduce their exposure to harmful and potentially harmful constituents (HPHCs). This study assessed changes in exposure to HPHCs, assessed via biomarkers of exposure (BOEs), among adults who switched to a new ENDS product.

Methods: Adults who smoke cigarettes (N = 89) were randomized to: (1) switch completely to using JUUL2 Virginia Tobacco (N = 24) or Polar Menthol (N = 24); (2) continue smoking usual brand (UB) cigarettes (N = 21); or (3) abstain from all tobacco/nicotine products (N = 20) for six days.

View Article and Find Full Text PDF

Background: People who inject drugs (PWID) are especially vulnerable to harms from opioid use disorder (OUD). Medications for OUD (MOUD) effectively reduce overdose and infectious disease transmission risks.

Objective: We investigate whether state Medicaid coverage for methadone and buprenorphine is related to past-year MOUD use among PWID using cross-sectional, multilevel analyses with individual-level data on PWID from the Centers for Disease Control and Prevention's 2018 National HIV Behavioral Surveillance.

View Article and Find Full Text PDF

Background: Little attention has been paid to the experiences of clinicians and health personnel who provide heroin-assisted treatment (HAT). This study provides the first empirical findings about the clinicians' experiences of providing HAT in the Norwegian context.

Methods: 23 qualitative interviews were conducted with 31 clinicians shortly after HAT clinics opened in Norway's two largest cities: Oslo and Bergen.

View Article and Find Full Text PDF

Introduction: IQOS was sold in the US in 2019-2021 and will likely return in 2024. It is important to anticipate IQOS' market penetration; thus, this study examined US adults' prior awareness and perceptions, intentions to try and reactions to an IQOS reduced-risk exposure statement.

Methods: 61 adults from three US cities were recruited to represent four tobacco use subgroups: current cigarette and never electronic nicotine delivery systems (ENDS) use; current cigarette and discontinued ENDS use; current cigarette and ENDS use; and former cigarette use and switched to ENDS.

View Article and Find Full Text PDF

The ANRS-Coquelicot survey has been carried out in France for 25 years, to monitor trends in infectious diseases (HIV and hepatitis B and C) among people who use drugs. In this article, we propose to open the black box of this monitoring experience, by describing and analysing some methodological, ethical and political issues involved in this type of survey. The ANRS-Coquelicot survey has carried out on five occasions in France (from 2002 to 2024) in several cities (from 1 to 27) among people who use drugs recruited in a large diversity of services including drug treatment centres, harm reduction facilities, residential services as well as outreach teams.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!